Eva Van den Eynde

767 total citations
25 papers, 273 citations indexed

About

Eva Van den Eynde is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Eva Van den Eynde has authored 25 papers receiving a total of 273 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 8 papers in Virology and 8 papers in Hepatology. Recurrent topics in Eva Van den Eynde's work include HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and HIV/AIDS Research and Interventions (7 papers). Eva Van den Eynde is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV Research and Treatment (8 papers) and HIV/AIDS Research and Interventions (7 papers). Eva Van den Eynde collaborates with scholars based in Spain, United States and Palestinian Territory. Eva Van den Eynde's co-authors include Esteban Ribera, Adrián Curran, Vicenç Falcó, Joaquín Burgos, Daniel Podzamczer, Jordi Navarro, Manuel Crespo, Albert Pahissa, I Ocaña and H. Verachtert and has published in prestigious journals such as Clinical Infectious Diseases, Biochemical Journal and AIDS.

In The Last Decade

Eva Van den Eynde

21 papers receiving 265 citations

Peers

Countries citing papers authored by Eva Van den Eynde

Since Specialization

Citations

This map shows the geographic impact of Eva Van den Eynde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Van den Eynde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Van den Eynde more than expected).

Fields of papers citing papers by Eva Van den Eynde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Van den Eynde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Van den Eynde. The network helps show where Eva Van den Eynde may publish in the future.

Co-authorship network of co-authors of Eva Van den Eynde

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Van den Eynde. A scholar is included among the top collaborators of Eva Van den Eynde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Van den Eynde. Eva Van den Eynde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Validation of N Protein Antibodies to Diagnose Previous SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers: Use of Roche Elecsys® Immunoassay in the S Protein Vaccination Era 2023 ·Viruses ·(unknown), (unknown), (unknown), (unknown), Rosa Serrano, Eva Van den Eynde, Marta Navarro, Joan Calvet, Jordi Gratacós, Mateu Espasa, (unknown)	1
2	Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers 2022 ·Viruses ·(unknown), Antonio Berenguer, (unknown), (unknown), Mateu Espasa, Sara Rodrı́guez, (unknown), Eva Van den Eynde, Marta Navarro, Joan Calvet, Jordi Gratacós, Rosa Serrano, (unknown), María José Amengual	7
3	Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital 2021 ·Infectious Diseases ·Eva Van den Eynde, Oriol Gasch, Joan Carles Oliva, (unknown), Sònia Calzado, (unknown), (unknown), Luis Falgueras, (unknown), (unknown), Sílvia Capilla, (unknown), J. Oristrell, (unknown), Mireia Navarro	20
4	Manejo clínico y tratamiento de los pacientes con hepatitis B 2016 ·Enfermedades Infecciosas y Microbiología Clínica ·Eva Van den Eynde, Mar Riveiro‐Barciela	2
5	Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients 2015 ·AIDS ·Eva Van den Eynde, Jordi Curto, Elena Ferrer, Arkaitz Imaz, María Saumoy, (unknown), Antonia Vila, Daniel Podzamczer	0
6	Switch strategies in antiretroviral therapy regimens 2014 ·Expert Review of Anti-infective Therapy ·Eva Van den Eynde, Daniel Podzamczer	11
7	ACTG‐HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO‐STR study 2014 ·Journal of the International AIDS Society ·Daniel Podzamczer, (unknown), Peré Domingo, Antonio Ocampo, Eva Van den Eynde, (unknown), (unknown), Hernando Knobel, Juan Pasquau, Antonio Antela, Manuel Crespo, B Clotet, (unknown), Pedro L. Sánchez, Paloma Geijo, (unknown), (unknown), (unknown), (unknown)	6
8	Tropical Diseases Screening in Immigrant Patients with Human Immunodeficiency Virus Infection in Spain 2013 ·American Journal of Tropical Medicine and Hygiene ·Fernando Salvador, Israel Molina, Elena Sulleiro, Joaquín Burgos, Adrián Curran, Eva Van den Eynde, S Villar del Saz, Jordi Navarro, Manuel Crespo, I Ocaña, Esteban Ribera, Vicenç Falcó, Albert Pahissa	43
9	Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen 2012 ·Journal of Antimicrobial Chemotherapy ·Joaquín Burgos, Manuel Crespo, Vicenç Falcó, Adrián Curran, Arkaitz Imaz, Peré Domingo, Daniel Podzamczer, (unknown), Eva Van den Eynde, (unknown), Esteban Ribera	14
10	Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients 2012 ·Journal of Antimicrobial Chemotherapy ·Joaquín Burgos, Manuel Crespo, Vicenç Falcó, Adrián Curran, Jordi Navarro, Arkaitz Imaz, Peré Domingo, Daniel Podzamczer, (unknown), (unknown), Eva Van den Eynde, Esteban Ribera, A Pahissa	13
11	HIV, HEV and cirrhosis: evidence of a possible link from eastern Spain 2012 ·HIV Medicine ·Rosendo Jardí, Manuel Crespo, María Homs, Eva Van den Eynde, Rosina Gironés, Jesús Rodríguez-Manzano, Andrea Caballero, Marı́a Buti, Rafael Esteban, Francisco Rodríguez‐Frias	43
12	Long-Term Effectiveness of First-Line Antiretroviral Theraphy in a Cohort of HIV-1 Infected Patients 2012 ·Journal of Antivirals & Antiretrovirals ·Jordi Navarro, Manuel Crespo, Vicenç Falcó, Eva Van den Eynde	0
13	Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital 2012 ·HIV Medicine ·Mar Riveiro‐Barciela, Vicenç Falcó, Joaquín Burgos, Adrián Curran, Eva Van den Eynde, Jordi Navarro, S Villar del Saz, I Ocaña, Esteban Ribera, (unknown), Albert Pahissa	16
14	Switch from efavirenz to nevirapine, with full dose after one week: efficacy, safety and pharmacokinetics 2012 ·Journal of the International AIDS Society ·Adrián Curran, (unknown), Eva Van den Eynde, M.J. Rubio Pérez, Joaquín Burgos, Jordi Navarro, Vicenç Falcó, S Villar del Saz, I Ocaña, Esteban Ribera	0
15	Invasive Pneumococcal Disease in HIV-Infected Adults 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joaquín Burgos, María Luz Pintos Peñaranda, Antoni Payeras, Aroa Villoslada, Adrián Curran, Margarita Garau, Melcior Riera, Manuel Crespo, Jordi Navarro, Eva Van den Eynde, Ana María Planes, Esteban Ribera, Albert Pahissa, Vicenç Falcó	14
16	Abacavir Coadministration Does Not Interfere with the Suppressive Activity of Ribavirin in An HCV Replicon System 2011 ·Antiviral Therapy ·Eva Van den Eynde, Josep Quer, María Cubero, Adrián Curran, María Homs, Damir García‐Cehic, Vicenç Falcó, Esteban Ribera, Juan Ignacio Esteban, Albert Pahissa, Manuel Crespo	4
17	Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients 2010 ·AIDS ·Eva Van den Eynde, Juan Tiraboschi, Cristina Tural, Ricard Solà, José Antonio López Mira, Daniel Podzamczer, Antoni Jou, Núria Cañete, Juan A. Pineda, Albert Pahissa, Manuel Crespo	8
18	Response‐Guided Therapy for Chronic Hepatitis C Virus Infection in Patients Coinfected with HIV: A Pilot Trial 2009 ·Clinical Infectious Diseases ·Eva Van den Eynde, Manuel Crespo, Juan Ignacio Esteban, R Jardí, Esteban Ribera, (unknown), Francisco Rodríguez‐Frias, Vicenç Falcó, Adrián Curran, Arkaitz Imaz, S Villar del Saz, I Ocaña, Rafael Esteban, Albert Pahissa	15
19	Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen 2008 ·Journal of Antimicrobial Chemotherapy ·Manuel Crespo, (unknown), Juan A. Pineda, Eva Van den Eynde, Maria José Ríos-Villegas, Antonio Collado, J.A. Girón González, Luís F. López‐Cortés, Mercedes González‐Serrano, Antonio Rivero, (unknown), Rafael Esteban	11
20	Soft and hard tissue reactions towards implant design and surface characteristics and the influence of plaque and/or occlusal loads 1993 ·Daniël van Steenberghe, Jorge Tricio, Eva Van den Eynde, Ignace Naert, Marc Quirynen	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact